<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Yestino - The Signal · Lilly</title><link>https://yestino.com/entities/lilly-55d9bb</link><description>Every event involving Lilly</description><language>en</language><atom:link href="https://yestino.com/entities/lilly-55d9bb/feed.xml" rel="self" type="application/rss+xml"/><item><title>Novartis heart drug&apos;s trial failure cast doubt on Amgen and Lilly&apos;s cholesterol race</title><link>https://yestino.com/events/novartis-heart-drug-s-trial-failure-cast-doubt-on-amgen-and-f8a6a4</link><guid isPermaLink="true">https://yestino.com/events/novartis-heart-drug-s-trial-failure-cast-doubt-on-amgen-and-f8a6a4</guid><pubDate>Tue, 08 Sep 2026 13:00:40 GMT</pubDate><description>Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
Sources: Quartz</description></item></channel></rss>